Supercharging Discovery with Novel Technologies to Deconvolute MOAs, Elucidate Target Biology & Accelerate GPCR Drug Design
The GPCR field is entering its next phase of innovation. As biopharma looks beyond GLP-1 therapeutics for the next breakthrough opportunity, advances in AI-enabled drug discovery, GPCR structural biology, cryo-EM, structure-guided drug design, next-generation screening technologies, and GPCR signaling biology are transforming how researchers discover, validate, and drug novel GPCR targets. Yet critical challenges remain, from de-risking orphan GPCRs and advancing GPCR target validation to predicting functional activity and translating complex receptor biology into differentiated medicines.
The 6th GPCR-Targeted Drug Discovery Summit is the industry's only dedicated meeting focused exclusively on the future of GPCR drug discovery, bringing together leaders advancing next-generation GPCR therapeutics across targets, modalities, and therapeutic areas. Join experts from Eli Lilly, Pfizer, Roche, Recursion Pharmaceuticals, Alphamol, LEMBAS, Kainova Therapeutics, Duke University, University of Miami, and more to benchmark the latest advances in AI for GPCR drug discovery, orphan GPCR drug discovery, GPCR signaling, target validation, structure-based drug design, and emerging therapeutic modalities including antibodies, peptides, biologics, and ADCs.
Whether you're searching for the next target beyond GLP-1, exploring emerging GPCR targets, evaluating novel therapeutic modalities, or accelerating your pipeline through GPCR-targeted drug discovery, join 80+ industry and academic experts shaping the next GPCR success story and defining the future of drug discovery.
Attending Companies Include